Skip to main content
. Author manuscript; available in PMC: 2014 May 15.
Published in final edited form as: Bioconjug Chem. 2013 Apr 24;24(5):803–810. doi: 10.1021/bc300613h

Figure 2.

Figure 2

Conceptual representation of an application envisioned for dL5_EAK membranes in vivo. In this scenario, membranes composed of dL5_EAK and EAK16-II would be used to intercept trafficking of inflammation-associated leukocytes to lymph nodes. Antibodies conjugated with MG would be introduced at the site of inflammation to label trafficking leukocytes. Association of cells with dL5_EAK could be detected by MG fluorescence generated by binding of MG and the FAP domain.